Prevention of chronic renal allograft rejection by SERP-1 protein

Transplantation

Volumn 81, Issue 6, 2006, Pages 908-914

  Bédard, Eric L R ^a,b   Jiang, Jifu ^a,b   Arp, Jacqueline ^c   Qian, Hua ^a,b   Wang, Hao ^a,b   Guan, Haiyan ^c   Liu, Liying ^c   Parry, Neil ^a,b   Kim, Peter ^a,b   Garcia, Bertha ^b   Li, Xing ^d   Macaulay, Colin ^d   McFadden, Grant ^b,c   Lucas, Alexandra ^b,c   Zhong, Robert ^a,b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d Viron Therapeutics Inc   (Canada)

Author keywords

Chronic; Kidney; Rat; Rejection; SERP 1

Indexed keywords

CYCLOSPORIN A; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; GLOMERULOSCLEROSIS; KIDNEY ALLOGRAFT REJECTION; LOW DRUG DOSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; VASCULAR NECROSIS;

ANIMALS; CHRONIC DISEASE; GRAFT REJECTION; KIDNEY TRANSPLANTATION; RATS; RATS, INBRED F344; RATS, INBRED LEW; RNA, MESSENGER; SERPINS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS; VIRAL PROTEINS;

EID: 33645636750     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203141.02725.8a     Document Type: Article

References (31)

1. Paul LC. Chronic allograft nephropathy-a model of impaired repair from injury? Nephrol Dial Transplant 2000; 15(2): 149-151.
2. Furness PN. Histopathology of chronic renal allograft dysfunction. Transplantation 2001; 71(11 Suppl): SS31-SS36.
3. Monaco AP, Burke JF Jr., Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33(1): 150-160.
4. Nash P, Barrett J, Cao JX, et al. Immunomodulation by viruses: the myxoma virus story. Immunol Rev 1999; 168: 103-120.
5. McFadden G, Graham K, Ellison K, et al. Interruption of cytokine networks by poxviruses: lessons from myxoma virus. J Leukoc Biol 1995; 57(5): 731-738.
6. Macen JL, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993; 195(2): 348-363.
7. Lomas DA, Evans DL, Upton C, et al. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem 1993; 268(1): 516-521.
8. Upton C, Macen JL, Wishart DS, McFadden G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 1990; 179(2): 618-631.
9. Nash P, Whitty A, Handwerker J, et al. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J Biol Chem 1998; 273(33): 20982-20991.
10. Bot I, von der Thusen JH, Donners MM, et al. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93(5): 464-471.
11. Lucas A, Liu L, Macen J, et al. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 1996; 94(11): 2890-2900.
12. Lucas A, Dai E, Liu L, et al. Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 2000; 19(11): 1029-1038.
13. Hausen B, Boeke K, Berry GJ, Morris RE. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation 2001; 72(3): 364-368.
14. Miller LW, Dai E, Nash P, et al. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 2000; 101(13): 1598-1605.
15. Dai E, Guan H, Liu L, et al. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 2003; 278(20): 18563-18572.
16. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90(1): 1-7.
17. Waller JR, Nicholson ML. Molecular mechanisms of renal allograft fibrosis. Br J Surg 2001; 88(11): 1429-1441.
18. Shihab FS, Yamamoto T, Nast CC, et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995; 6(2): 286-294.
19. Shihab FS, Tanner AM, Shao Y, Wetter MI. Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50(6): 1904-1913.
20. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69(9): 1759-1766.
21. Chin J, Zhong R, Duff J, Stiller C. Microsurgical renal transplant models in rats: a comparison of four anastomotic techniques. Transplant Proc 1989; 21(2): 3351-3352.
22. Densem CG, Hutchinson IV, Cooper A, et al. Polymorphism of the transforming growth factor-beta 1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J Heart Lung Transplant 2000; 19(6): 551-556.
23. Nicholson ML, Waller JR, Bicknell GR. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA. Br J Surg 2002; 89(7): 933-937.
24. Van Obberghen-Schilling E, Roche NS, Flanders KC. et al. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263(16): 7741-7746.
25. Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51(5): 1388-1396.
26. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996; 10(9): 1077-1083.
27. Azuma H, Nadeau K, Takada M, et al. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation 1997; 64(2): 190-197.
28. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93(3): 1172-1178.
29. Border WA, Okuda S, Languino LR, et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346(6282): 371-374.
30. Rerolle JP, Hertig A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58(5): 1841-1850.
31. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22(3): 499-505.